Literature DB >> 30350532

The role of the pathologist and clinical implications in colorectal liver metastasis.

P Baldin1, M Van den Eynde2, C Hubert3, A Jouret-Mourin1, M Komuta1.   

Abstract

Colorectal liver metastases (CRLM) affect about 50% of colorectal cancer patients. With the improvement of neoadjuvant chemotherapy and the introduction of targeted therapy, resectability of CRLM and survival rates have improved over time. However, 60-70% of patients still recur. Several pathological and molecular parameters have been described as prognostic factors after CRLM resection. These parameters encompass not only tumoral features, but also non-tumoral ones, such as chemotherapy related liver injury, or factors related to tumour environment, namely Immunoscore. This review summarizes these prognostic indicators to clarify which patho-molecular parameters should be addressed in the pathological report. © Acta Gastro-Enterologica Belgica.

Entities:  

Keywords:  RAS; chemotherapy related liver injury; histopathological growth pattern; immunoscore; prognostic scoring system; tumour regression grading

Mesh:

Substances:

Year:  2018        PMID: 30350532

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  2 in total

Review 1.  Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.

Authors:  Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix
Journal:  Br J Cancer       Date:  2022-06-01       Impact factor: 9.075

2.  Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).

Authors:  Pamela Baldin; Javier Carrasco; Gabriela Beniuga; Anne Jouret-Mourin; Gauthier Demolin; Sandrine Roland; Lionel D'Hondt; Philippe Vergauwe; Daniel Van Daele; Marie Mailleux; Isabelle Sinapi; Astrid De Cuyper; Noëlla Blétard; Brigitte Massart; Monique Delos; Marie-Laure Castella; Aline van Maanen; Marc Van den Eynde
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.